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Abstract: The Kunitz-type protease inhibitors are the best-characterized family of serine 
protease inhibitors, probably due to their abundance in several organisms. These inhibitors 
consist of a chain of ~60 amino acid residues stabilized by three disulfide bridges, and was 
first observed in the bovine pancreatic trypsin inhibitor (BPTI)-like protease inhibitors, 
which strongly inhibit trypsin and chymotrypsin. In this review we present the protease 
inhibitors (PIs) described to date from marine venomous animals, such as from sea 
anemone extracts and Conus venom, as well as their counterparts in terrestrial venomous 
animals, such as snakes, scorpions, spiders, Anurans, and Hymenopterans. More emphasis 
was given to the Kunitz-type inhibitors, once they are found in all these organisms. Their 
biological sources, specificity against different proteases, and other molecular blanks 
(being also K
+
 channel blockers) are presented, followed by their molecular diversity. 
Whereas sea anemone, snakes and other venomous animals present mainly Kunitz-type 
inhibitors, PIs from Anurans present the major variety in structure length and number of  
Cys residues, with at least six distinguishable classes. A representative alignment of PIs 
from these venomous animals shows that, despite eventual differences in Cys assignment, 
the key-residues for the protease inhibitory activity in all of them occupy similar positions 
in primary sequence. The key-residues for the K
+
 channel blocking activity was also compared. 
Keywords: protease inhibitor; Kunitz-type; serine protease; toxin; trypsin;  
chymotrypsin; venom  
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Protease inhibitors (PIs) are proteins or peptides capable of inhibiting the catalytic activity of 
proteolytic enzymes. They are widely distributed in nature and can be found in all kingdoms of cellular 
life and also in viral genomes [1,2]. A typical mammalian genome contains 2%–4% of genes encoding 
for proteases or protease inhibitors, reflecting the importance of proteolysis in their biological 
processes [3]. PIs have been known since the end of 20th century, and their identification can become 
more effective nowadays because of the current appliance of protease degradomics [4], which in 
association with proteomic tools and enzymatic assays can lead to the characterization of innumerous 
novel protease inhibitors. 
Interest in characterizing new PIs and understanding their physiological significance has increased 
due to their biological relevance for all living processes, such as blood coagulation system, 
complement cascade, apoptosis, cell cycle and hormone processing pathways [5–8]. Furthermore, 
deficiencies or alterations in the regulation of these enzymes underlie several pathological conditions, 
such as cancer, arthritis, neurodegenerative and cardiovascular diseases [9,10]. 
According to the proteases they inhibit, PIs can be grouped primarily as serine, cysteine, aspartic 
and metallo protease inhibitors [11]. Among these, serine protease inhibitors are the largest and most 
widely distributed superfamily of PIs [1,12,13], and based upon their possession of conserved 
functional motifs they can be subdivided in many classes, being the Kunitz-type inhibitors the best 
characterized of them, probably due to their abundance in several organisms [2,14–17]. The  
Kunitz-type motif consists of a polypeptide chain of ~60 amino acid residues stabilized by three 
disulfide bridges (CI–CVI, CII–CIV, CIII–CV). The Kunitz-type inhibitors interact with proteases by the 
classical substrate-like mechanism [13] mainly through the P1–S1 interaction, based on the 
nomenclature of Schechter and Berger [18]. The standard mechanism implies that substrates/inhibitors 
contain the reactive site residues P3, P2, P1, P1′, P2′, P3′, located in the most exposed region of the 
protease-binding loop, that bind to the substrate amino acid side chains S3, S2, S1, S1′, S2′, S3′, which 
form the groove or cleft where amide bond hydrolysis occurs. Non-prime and prime designations 
specify amino- and carboxy-terminal sides of cleavage site, respectively [11,18]. The Kunitz-type 
motif was first observed in the bovine pancreatic trypsin inhibitor (BPTI)-like protease inhibitors, 
which strongly inhibit serine proteases such as trypsin and chymotrypsin [19–21]. 
In this review we present the protease inhibitors described to date from marine venomous animals, 
most of which have been obtained from sea anemone extracts, but also from Conus species, as well as 
their counterparts in terrestrial venomous animals, such as snakes, scorpions, spiders, frogs and toads, 
and bees and wasps. Due to the big amount of data, we have given more emphasis on the Kunitz-type 
serine protease inhibitors, once they are the most studied compounds among PIs and are found in all 
these organisms. Initially, the PIs are presented according to their biological sources, together with 
their main characteristics and activities against different proteases. Then, their dual function including 
potassium channel blocking activity is discussed, followed by the molecular diversity of protease 
inhibitor compounds. 
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2. Protease Inhibitors from Sea Anemones 
The first reports on the existence of protease inhibitors in sea anemones species date from the  
70s [22,23]. Currently, protease inhibitor peptides and neurotoxins are isolated from sea anemone 
whole bodies, tentacles, secreted mucus and aggressive organs such as acrorhagi, which is present in 
some species from Actiniidae family [24].  
Several PIs have already been isolated or partially purified and characterized from the sea  
anemone species Actinia equina [24–26], Anemonia sulcata [27–30], Radianthus koseirensis [31],  
Heteractis crispa (also named Radianthus macrodactylus) [32–34], Rhodactis rhodostoma [31], 
Stoichactis sp. [35], Stoichactis helianthus [36–39], Stichodactyla haddoni [40], Anthopleura aff. 
xanthogrammica [24,41], Anthopleura elegantissima [42] and Anthopleura fuscoviridis [24] (Table 1). 
Most of these characterized PIs are homologous to Kunitz-type inhibitors. However, some of them 
belong to different superfamilies. 
Table 1. Protease inhibitors from venomous animals. Some protease inhibitors with less 
information about sequence or biological activity, as well as some putative protease 
inhibitors only found by means of transcriptomic approach but not tested against proteases, 
were not included in this table (some of them are found within the text, with the respective 
UniProtKB code). Organisms from which the PIs were obtained are indicated by the 
symbols at left: # sea anemones; + snakes; § scorpions; ¥ spiders; ¤ Anurans;  
ø Hymenopterans. Capital letters denote the proteases inhibited: T, trypsin; C, 
chymotrypsin; CL, cathepsin L; CB, cathepsin B; P, papain; K, kallikrein; PK, plasma 
kallikrein; TK, tissue kallikrein; Pl, plasmin; E, elastase; nE, neutrophil elastase; pE, 
pancreatic elastase; X, factor Xa; XII, α-factor XIIa; SA, subtilisin A; ptK, proteinase K; 
Th, thrombin. Structural classes are indicated by symbols: ♦ Kunitz-type motif protease 
inhibitors; ∎ Kazal-type protease inhibitors; ● thyroglobulin type-1domain; ◊ Ascaris-type 
motif;  Bowman-Birk-type motif. 
Specie Toxin UniProt KB AA a Protease inhibited Inhibitory activity b–g References 
# Actinia equina 
♦ AEPI-I - 59 III - - [26] 
♦ AEPI-II - 59 III - - [26] 
● Equistatin P81439 199 III 
Cathepsin L *,  
papain,  
cathepsin B 
0.051 (CL),  
0.57 (P),  
1.4 (CB) b 
[25,43] 
♦ AEAPI - 57 III Trypsin *, plasmin 700 IU/mg (T) c [24] 
# Anemonia sulcata 
■ Elastase inhibitor P16895 48 III Porcine elastase 1.0 d [28,44] 
♦ Kalicludin-1 or AsKC1 Q9TWG0 58 III Trypsin <30 d [27] 
♦ Kalicludin-2 or AsKC2 Q9TWF9 58 III Trypsin <30 d [27] 
♦ Kalicludin-3 or AsKC3 Q9TWF8 59 III Trypsin <30 d [27] 
♦ SA5 II P10280 62 III Kallikrein, Trypsin 0.3 (T) d [29,32] 
# Anthopleura aff. 
xanthogrammica 
♦ AXPI-I or AXAPI P81547 58 III 
Trypsin *, chymotrypsin, 
elastase, thermolysin 
1900 IU/mg (T) c [24,41] 
♦ AXPI-II P81548 58 III Trypsin *, chymotrypsin 490 IU/mg (T) c [41] 
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# Anthopleura elegantissima ♦ APEKTx1 P86862 65 III Trypsin 124 d [42] 
# Anthopleura fuscoviridis 
♦ AFAPI-I - 56 III Trypsin *, plasmin 950 IU/mg (T) d [24] 
♦ AFAPI-III - 56 III Trypsin *, plasmin 900 IU/mg (T) d [24] 
# Heteractis crispa 
♦ Jn-IV P16344 56 III Trypsin 9.6 d [32,33] 
♦ InhVJ - 56 III 
Trypsin *,  
chymotrypsin  
2.49 (T),  
21.7 (C) d 
[45–47] 
♦ APHC1 B2G331 56 III 
Trypsin,  
chymotrypsin 
1000 (T),  
~5000 (C) d 
[34] 
# Rhodactis rhodostoma ♦ Inhibitor 4 - 48 II 
Trypsin,  
kallikrein *,  
chymotrypsin 
0.95 (T),  
0.49 (K),  
33 (C) d 
[31] 
# Stichodactyla haddoni ♦ SHTX-3 B1B5I8 62 III Trypsin 203 IU/mg c [40] 
# Stoichactis helianthus 
♦ ShPI-1 P31713 55 III 
Serine *,  
cysteine,  
aspartic proteases 
0.11 (T),  
2.3 (C),  
2.7 (Pl) d 
[36,37] 




+ Dendroaspis polylepis 
polylepis 
♦ Dendrotoxin E P00984 59 III 
Trypsin *,  
chymotrypsin 
1.0 (T),  
100 (C) d 
[48] 
+ Daboia siamensis 
♦ BBPTI-1 - 60 III Chymotrypsin 4.77 b [49] 
♦ CBPTI-1 A8Y7N4 66 III Trypsin 407 b [50] 
♦ CBPTI-2 A8Y7N5 60 III Trypsin 666 b [50] 
♦ CBPTI-3 A8Y7N6 60 III Chymotrypsin 2.55 b [50] 





+ Naja nivea ♦ NNV inhibitor II P00986 57 III Trypsin - [51] 
+ Vipera ammodytes 




0.34 (T),  
270 (C) b 
[52,53] 




0.56 (T),  
300 (C) b 
[52] 




4.3 (C),  
5100 (T) b 
[52] 
+ Bungarus fasciatus 
♦ BF9 P25660 65 III Chymotrypsin 58 d [54] 
♦ Bungaruskunin B2KTG1 59 III 
Chymotrypsin *, 
trypsin, elastase 
6100 (C) b [55] 
+ Naja naja ♦ Trypsin inhibitor P20229 57 III Trypsin 0.0035 b [56] 
+ Naja atra ♦ NACI Q5ZPJ7 57 III Chymotrypsin 25 b [57,58] 
+ Ophiophagus hannah 
♦ Oh11-1 P82966 58 III Chymotrypsin 3520 b [59] 
♦ OH-TCI B6RLX2 58 III 
Chymotrypsin *, 
trypsin 
84.6 (C),  
391 (T) b 
[60] 
+ Bungarus multicinctus ♦ PILP-1 B4ESA2 58 III Trypsin 55.62 b [61] 
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+ Oxyuranus scutellatus 
scutellatus 
♦ TSPI B7S4N9 62 III 
Kallikrein *,  
trypsin, plasmin, 
elastase, factor Xa,  
α-factor XIIa 
0.057 (PK),  
0.23 (TK),  
0.31 (T), 6.1 (Pl),  
201 (E), 871 (X),  
2380 (XII) b 
[62,63] 
+ Pseudonaja textilis 
textilis 
♦ Textilinin-1 Q90WA1 59 III 
Plasmin *,  
trypsin 
0.49 ± 0.02 (Pl),  
0.76 ± 0.02 (T) b 
[7,63] 
♦ Textilinin-2 Q90WA0 59 III Plasmin 2.2 b [7] 
+ Macrovipera lebetina 
transmediterranea 
♦ PIVL I2G9B4 67 III Trypsin - [64] 
+ Pseudechis australis 
♦ Pr-mulgin 1 E7FL11 59 III Metalloprotease 2 60 b [65] 
♦ Pr-mulgin 2 E7FL12 59 III 
Trypsin *,  
chymotrypsin,  
plasmin 
5 (T),  
40 (C),  
40 (Pl) b 
[65] 
♦ Pr-mulgin 3 E7FL13 59 III 
Trypsin,  
plasmin 
5 (T),  
100 (Pl) b 
[65] 
§ Mesobuthus tamulus ♦ Fraction IX-1-a - - 
Trypsin *,  
kallikrein 
19.2 IU/mg (T),  
87 IU/mg (K) c 
[66] 
§ Hadrurus gertschi ♦ rHg1 P0C8W3 67 III Trypsin 107 d [67,68] 
§ Lychas mucronatus 
♦ rLmKTT-1a P0DJ46 59 III Trypsin 140 d [16,68] 
♦ rLmKTT-1b or SdPI P0DJ45 59 III Trypsin 160 d [16,68] 
♦ rLmKTT-1c P0DJ48 59 III Trypsin 124 d [68] 
§ Mesobuthus martensii 
♦ rBmKTT-1 P0DJ49 59 III Trypsin 136 d [68] 
♦ rBmKTT-2 P0DJ50 58 IV Trypsin 420 d [68] 
♦ rBmKTT-3 P0DJ47 70 III Trypsin 760 d [68] 
§ Scorpiops jendeki ◊ rSjAPI - 64 V 
Chymotrypsin *,  
elastase 
97.1 (C),  
3700 (E) b 
[69] 
¥ Ornithoctonus huwena ♦ HWTX-XI P68425 55 III Trypsin 0.23 d [14] 
¥ Araneus ventricosus 
♦ AvKTI K7YYJ2 57 III 
Trypsin, 
chymotrypsin,  
plasmin *,  
neutrophil elastase 
7.34 (T),  
37.75 (C),  
4.89 (Pl),  
169.07 (E) b 
[70] 
♦ AvCI L7X735 70 IV 
Chymotrypsin,  
subtilisin A,  
proteinase K,  
neutrophil elastase,  
pancreatic elastase 
49.85 (C),  
20.51 (SA),  
65.42 (ptK),  
8.74 (nE),  
11.32 (pE) b 
[71] 
¤ Bombina bombina ◊ BSTI Q90248 60 V 
Trypsin,  
thrombin 
80–100 (T),  
1300 (Th) b 
[72] 
¤ Bombina maxima ◊ BMTI Q8QFP3 60 V Trypsin 60 b [73] 
¤ Rana areolata ◊ Trypsin inhibitor - 61 V Trypsin ~20,000 e [74] 
¤ Bombina orientalis ◊ BOTI Q800F0 60 V - - [75] 
¤ Bombina variegata ◊ BVTI Q800E9 60 V - - [75] 
¤ Bombina 
microdeladigitora 
◊ BMSI 1 B1P2F8 60 V Trypsin, thrombin 20 (T), 150 (Th) b [76] 
◊ BMSI 2 B1P2F9 60 V - - [76] 
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¤ Hyla simplex 
Hylaserpin S1 H6SWK9 392 
Trypsin,  
chymotrypsin 
55 (T),  
310 (C) b 
[77] 
◊ Hylaserpin S2 H6SWL0 56 V Trypsin 72 b [77] 
¤ Bufo andrewsi 
BATI - - Trypsin 14 b [78] 




4.6 × 106 (T),  
8.9 × 106 (C),  
6.8 × 106 (E) f 
[79] 
¤ Kaloula pulchra hainana KPHTI - - Trypsin 27 c [80] 
¤ Phyllomedusa sauvagii 
■ PSKP-1 P83578 58 III Prolyl endopeptidase 124 ± 56 g [81] 
■ PSKP-2 P83579 58 III - - [81] 
¤ Phyllomedusa nordestina 
PI01 K9N0E2 78 III - - [82] 
PI02 K9N1K5 77 III - - [82] 
PI03 K9N2T9 53 III - - [82] 
¤ Agalychnis callidryas ■ ACKTI I7J523 52 III Trypsin 1.9 b [83] 
¤ Dyscophus guineti ♦ Kunitz-type PI J9UVV9 57 III Trypsin - [17] 
¤ Kassina senegalensis ♦ KSCI F8K9Q3 62 III Chymotrypsin - [84] 
¤ Hyla annectans ♦ Anntoxin C7AR58 60 II Trypsin 25 b [85] 
¤ Odorrana grahami OGTI - 17 II Trypsin 400 b [86] 
¤ Huia versabilis  HV-BBI B1VC43 18 I Trypsin 18.8 + 1.8 b [87] 
ø Vespa bicolor Fabricius ♦ Bicolin C0LNR2 54 III Trypsin *, thrombin 550 (T), 26,000 (Th) b [88] 
ø Bombus ignitus ♦ Bi-KTI G3LH89 58 III Plasmin 43.53 g, 3.6 b [6] 
ø Bombus terrestris ♦ Bt-KTI D8KY58 58 III Plasmin 2.01 b [89] 
* Protease against which the inhibitor showed more potent activity; a Number of amino acid residues and disulfide bridges (superscript) 
of the mature peptide; b Measured in terms of Ki value (nM); 
c Measured in terms of inhibitory units (IU)/mg, where 1 IU is the amount 
of protein that inhibit one unit of enzyme; d Measured in terms of Kd value (nM); 
e Unique concentration used (nM); f Association rate 
(kass) measured in M
−1·s−1; g Measured in terms of IC50 value (nM); n.f. means inhibitory activity not found by the authors; - Means data 
not available in the literature. 
Equistatin, a protease inhibitor isolated from the hydrophilic extract of the whole body of  
Actinia equina [25], is an acidic protein composed of three thyroglobulin type-1 domains [43]. It is 
encoded by a putative sequence of 231 amino acids, including the signal peptide [43]. Equistatin 
inhibits papain-like cysteine proteases, such as papain and cathepsin L, with lower affinity for 
cathepsin B (Table 1) [25]. It was further shown that the N-terminal domain alone acts as a Cys 
protease inhibitor (Ki of 0.6 nM for papain), and the second domain act as an aspartic protease 
inhibitor (Ki of 0.3 for cathepsin D). The function of the third domains remains unknown [90,91]. 
From the extracts of Anemonia sulcata it was isolated an elastase inhibitor (AEI) that was found to 
be a non-classical Kazal-type inhibitor with respect to positioning of the cysteine residues [28,30,44]. 
With 48 amino acid residues, its tridimensional structure resembles those of typical Kazal-type 
inhibitors, however, the disulfide bridge CI–CV in the sea anemone elastase inhibitor is shifted by one 
turn in the α-helical segment towards the C-terminal in comparison with those of Kazal-type’s [28,30]. 
The inhibitor strongly inhibits porcine pancreatic elastase (Table 1), with weaker activity against 
human leucocytes elastase (Ki of 1.0 µM). No inhibition was observed against other serine proteases 
such as bovine trypsin, bovine chymotrypsin, subtilisin from Bacillus subtilis and cathepsin G from 
human leucocytes [44]. 
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Type II toxins from sea anemone are a peptide group that block Kv1 channel currents—although 
with much less potency than the sea anemone type I toxins, which are potent Kv1 channel  
blockers [92]—and are characterized by a polypeptide chain of 58–63 amino acid residues and three 
disulfide bridges [42,93]. They are homologous to Kunitz-type inhibitors of serine proteases and their 
biological role is still unclear. It is supposed that these protease inhibitors could (1) defend sea 
anemones from the protease of their victims; (2) protect the toxins injected into preys or predators 
from fast degradation; (3) act on the regulation of digestive mechanisms, including self-digestion by 
their own enzymes or by those of symbiotic microorganism; (4) and also, due to their dual activity, 
they could also be used to paralyze preys [31,35,92]. 
Among these Kunitz-type inhibitor toxins (KTTs), the sea anemone kalicludines (AsKC1 to AsKC3, 
Table 1), from Anemonia sulcata, are examples of toxins with both protease inhibitor and potassium 
channel blocking activities (Table 2) [27]. With 58–59 amino acid residues cross-linked by three 
disulfide bridges, all the three kalicludines inhibit trypsin with very similar inhibition profiles, in a  
1:1 molar ratio, such as BPTI. From titration curves Kd values below 30 nM could be deduced [27]. 
Another KTT from A. sulcata is the Kunitz-type protease inhibitor 5 II (SA5 II, Table 1), which 
inhibits both tissue and plasma kallikreins [29]. Previous to these studies, at least ten KTTs with 
inhibitory effects against trypsin, chymotrypsin, plasmin and kallikrein have been reported from  
A. sulcata extracts [22,23]. 
Table 2. Potassium channel blocking activity of Kunitz-type motif protease inhibitor 
peptides from animal venoms. Scorpion and spider mutated peptides were not considered. 
Source Peptide IC50 (nM) Target Ref. 
Sea anemone 
APEKTx1 * 0.9 ± 0.1 Kv1.1 [42] 
AsKC1 * 2800 Kv1.2 [27] 
AsKC2 * 1100 Kv1.2 [27] 
AsKC3 * 1300 Kv1.2 [27] 
SHTX-3 * 650 Synap 
a
 [40] 
Cone snail Conk-S1 1.33 ± 0.5 Shaker [94] 
Snake 
α-DTX 0.4–150 Kv1.1, Kv1.2, Kv1.6 [95] 
DTX-I 0.13–50 Kv1.1, Kv1.2, Kv1.6 [95] 
DTX-K 0.03 Kv1.1 [96] 
δ-DTX 0.029–1.8 Kv1.1 [96,97] 
DaE 300 Kv1.1 [98] 
Scorpion 
Hg1 * 6.2 ± 1.2 Kv1.3 [68] 
LmKTT-1a * 1580 Kv1.3 [68,99] 
LmKTT-1b * >1000 Kv1.3 [68] 
LmKTT-1c * >1000 Kv1.3 [68] 
BmKTT-1 * 129.7 ± 31.3 Kv1.3 [68] 
BmKTT-2 * 371.3 ± 82.1 Kv1.3 [68] 
BmKTT-3 * >1000 Kv1.3 [68] 
Spider HWTX-XI * 2570 Kv1.1 [14] 
* Peptides that also present protease inhibitory activity, as shown in Table 1; 
a
 Activity obtained through 
synaptosomal binding assay. 
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In the 80s, three protease inhibitors composed of 52–56 amino acid residues were isolated from 
Stoichactis sp. [35]. Inhibitors 2 and 3 had estimated molecular masses of ~6000 Da. Inhibitor 2, 
which was the main component, had its approximate molecular mass (5800 Da) determined by gel 
filtration. Inhibitors 2 and 3 lack tryptophan in their structures and contain two and three disulfide 
bridges, respectively. They both inhibited trypsin almost completely (98%) and, to a lesser extent, also 
chymotrypsin (86% and 92%, respectively). Inhibitor 1, which was still impure, presented a lower 
inhibitory activity (80% against trypsin and 50% against chymotrypsin).  
In the same decade, protease inhibitors were isolated from the body extracts of Radianthus 
koseirensis and Rhodactis rhodostoma [31]. From R. rhodostoma, the main protease inhibitor has  
5459 Da and only two disulfide bridges. Named inhibitor 4 (Table 1), it had a high affinity for serine 
proteases (trypsin, kallikrein and chymotrypsin), and was less active in terms of the molar ratio 
(enzyme:inhibitor). Whereas typical trypsin inhibitors act stoichiometrically 1:1, inhibitor 4 from  
R. rhodostoma had a ratio of 1:2 for trypsin and 1:2.4 for chymotrypsin and kallikrein. From  
R. koseirensis, an inhibitor fraction was obtained, but it had very low affinity for serine proteases and 
did not inhibit chymotrypsin. The authors suggest that the ineffectiveness towards serine proteases of 
R. koseirensis fraction may have its origin in the neutral to slightly acidic properties of its inhibitor 
molecule. Differently, PIs from R. rhodostoma are basic in nature, such as BPTI and many KTTs [31]. 
Until now, many PIs were isolated from the body extract of Heteractis crispa (=Radianthus 
macrodactylus), but only few of them were fully characterized. Protease inhibitors of about 6000 Da 
were obtained from a water-ethanol extract of H. crispa, and the primary structure was elucidated for 
one of them, named Kunitz-type trypsin inhibitor IV or Jn-IV (Table 1) [33]. After that, four trypsin 
inhibitors were isolated (InI–InIV), and one of them (InI) was partially characterized. Composed by  
59 amino acid residues, its molecular mass determined by SDS-PAGE was 7100 Da, whereas its 
molecular mass calculated by the amino acid composition was 6304 Da [100]. Posteriorly, two serine 
protease inhibitors were isolated [32]. RmIn I and RmIn II have 6322.8 and 6096.0 Da, respectively, 
according to their amino acid composition, and both have three disulfide bridges and no methionine or 
tryptophan residues [32], which is common in Kunitz-type protease inhibitors [35,51,101], with few 
exceptions (Figure 1). The N-terminal amino acid sequences of RmIn I and RmIn II were determined 
and they were 66%–86% identical with the analogous fragment of Kunitz-type trypsin inhibitor IV, 
isolated from the same source, suggesting that they are isoforms. Both RmIn I and RmIn II were active 
against trypsin and α-chymotrypsin, with Ki values of 2.4 and 2.5 nM for trypsin and 23 and 30 nM for 
α-chymotrypsin, respectively. Moreover, both polypeptides were not toxic to mice (10–100 µg of 
peptide per kg of animal) and exhibited antihistamine activity in a dose-dependent manner [32]. 
Also from Heteractis crispa extract, a Kunitz-type toxin designated as InhVJ was isolated  
(Table 1) [45,46]. It has 6106 Da, three disulfide bridges and also no Met or Trp residues [45,47].  
Its putative sequence encodes a 78-amino acid residues polypeptide, including a signal peptide with  
22 amino acid residues [47]. InhVJ is highly specific toward trypsin and α-chymotrypsin and did not 
inhibit other serine proteases (such as thrombin, kallikrein and plasmin), neither cysteine (papain) nor 
aspartic (pepsin) proteases [45,46]. Recently characterized, the analgesic polypeptide HC1  
(or APHC1), with 6187.0 Da, presents very weak inhibition against trypsin and chymotrypsin  
(Table 1), although it completely inhibits both at a 1:1 molar ratio. Its main activity is related to an 
analgesic effect due to modulation of mammalian TRPV1-receptors [34]. 
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The peptides ShPI-1 and ShPI-2 were obtained from the crude extract of Stoichactis helianthus. 
With 6110.6 Da and six cysteine residues, ShPI-1 was active against many proteases of different 
mechanistic classes [37]. It inhibited serine, cysteine and aspartic proteases, and did not affect the one 
metalloenzyme tested (bacterial collagenase). The strongest inhibition capacity was against trypsin  
(Ki = 1.1 × 10
−10
 M). Other serine proteases such as plasmin and chymotrypsin, and cysteine proteases 
(bromelain and papain) were inhibited with smaller intensity. The smallest degrees of inhibition were 
obtained against the serine protease kallikrein and elastase and against aspartic proteases [37].  
Four serine protease inhibitors (AEPI-I to -IV) were isolated from the sea anemone  
Actinia equina [26]. Whereas only 35 and 37 N-terminal amino acid residues were determined for 
AEPI-III and -IV, the complete primary sequence was determined to AEPI-I and -II, which contain  
59 amino acid residues and three disulfide bonds. Both peptides (Table 1) share structural similarity 
with Kunitz-type inhibitors, however, their protease inhibitory activity has not been measured yet. 
From the whole body extract of Stichodactyla haddoni, four peptide toxins were isolated and named 
SHTX-1 to SHTX-4 [40]. SHTX-1–3 induced paralysis in crabs with ED50 values of 430, 430 and  
183 µg/kg, respectively, exhibiting no lethality even at 1000 µg/kg. SHTX-4 was lethal to crab with  
an estimated LD50 of 93 µg/kg. Among them, SHTX-3 was the only one with an antitryptic activity 
(Table 1), as well as potassium channel blocking activity (Table 2). SHTX-3 toxin has 7035.0 Da and 
is cross-linked by three disulfide bridges. Its cloned gene encodes a putative sequence of 19 amino 
acid residues for the signal peptide and 62 for the mature peptide, without a propart between them. 
Because it was previously proposed that the propart with two basic residues at its end functions as a 
signal directing toxins into nematocyst [102], it is assumed that SHTX III is not contained in these 
stinging cnidarian organelles [40].  
AXPI-I and -II (Table 1) were isolated from the whole body extract of Anthopleura aff. 
xanthogrammica [41]. Both are basic peptides, with three disulfide bonds, 58 amino acid residues and 
belong to the Kunitz-type family. Both inhibited trypsin at a molar ratio of 2:1 (inhibitor: enzyme). 
AXPI-I was moderately or weakly inhibitory against the serine proteases α-chymotrypsin and elastase, 
and against the metallo-proteases thermolysin and Streptomyces griseus protease. AXPI-II also 
presented weak inhibition against α-chymotrypsin. Neither of them inhibited the cysteine proteases 
papain nor bromelain [41].  
AXAPI, which was another name given to AXPI-I (Table 1), was further isolated from the 
acrorhagial extract of this same species [24]. Since much higher protease inhibitory activity was 
displayed by the acrorhagi of A. aff. xanthogrammica (59 IU/mL) than the remaining tissues  
(2.9 IU/mL), the authors suggested that AXPI-I is derived from the acrorhagi. Competitive inhibition 
experiments with 
125
I-α-dendrotoxin and rat synaptosomal membranes suggest that this peptide has  
no potassium channel toxicity even at 10 µM [24]. In the same study, two Kunitz-type PIs that were 
purified from the acrorhagial extracts of Anthopleura fuscoviridis (AFAPI-I and AFAPI-III, Table 1) 
and one from Actinia equina (AEAPI, Table 1) were also described [24]. Similar to AXAPI,  
they all inhibited both trypsin and plasmin and did not inhibit potassium channels at the same 
concentration [24]. 
The toxin APEKTx1 was isolated from Anthopleura elegantissima and is slightly larger than most 
of the KTTs (Table 1) [42]. With 63 amino acid residues, 7468.5 Da and three disulfide bridges, this 
toxin inhibits serine proteases and also blocks potassium channels (Table 2), similar to the kalicludines 
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and SHTX-3 [27,40]. APEKTx1 is presumably a competitive trypsin inhibitor, with a dissociation 
constant (Kd) of 124 nM. However, a 3-fold molecular excess of toxin over trypsin was needed to 
completely inhibit the protease, which is about 3 times the amount of BPTI or the kalicludines 
necessary to reach total trypsin inhibition [42].  
3. PIs from Conus Venoms 
Conotoxins are small disulfide-rich peptide toxins from cone snails usually with 10–30 amino acid 
residues that have evolved from at least 16 genetically distinct superfamilies, many of which are 
subject to diverse types of posttranslational modifications, such as C-terminal amidation, 
hydroxyprolines, or glycosylation of serine or threonine [103,104]. They can be divided into several 
families according to the cysteine bridge pattern and biological activities [104]. In relation to most of 
Conus venom toxins, conkunitzin-S1 (Conk-S1, UniProtKB P0C1X2), from the venom of  
Conus striatus, is unusually long (60 amino acid residues) and has a C-terminal amidation as the only 
posttranslational modification [105]. This potassium channel pore-blocking polypeptide (Table 2) also 
belongs to the Kunitz-type inhibitor domain, although it is stabilized by only two of the three disulfide 
bridges normally found in KTTs [105]. 
The cDNA library constructed with the mRNA from Conus californicus venom ducts revealed the 
presence of four new putative Kunitz-type inhibitors (Cal9.1a to Cal9.1d, UniProtKB D2Y488, 
D2Y489, D2Y490 and D2Y491, respectively) [106]. The mature peptides of these four compounds 
have 56 amino acid residues and share high sequence identity. Despite having about the same length of 
the Conk-S1, these toxins have six cysteine residues. Their activity as protease inhibitors is still 
uncertain [106]. In addition, another putative Kunitz-type inhibitor (conkunitzin-B1, UniProtKB 
P0CY85) was obtained from the transcriptome of Conus bullatus venom ducts by means of  
next-generation sequencing techniques [107]. 
4. PIs from Terrestrial Venomous Animals  
4.1. PIs from Snake Venoms 
Similar to those from marine venomous animals, most of protease inhibitors characterized so far 
from snake venoms present the Kunitz-type motif. These snake venom polypeptides have been 
demonstrated to specifically inhibit the proteolytic activity of trypsin or chymotrypsin. However, some 
snake neurotoxins, such as dendrotoxins, calcicludine and B chain of β-bungarotoxin, possess  
a Kunitz/BPTI-like domain although they exhibit little or no protease inhibitory activity. 
In the beginning of 70’s, from the venom of the black mamba (Dendroaspis polylepis polylepis), the 
first trypsin inhibitor homologs (toxins I and K) were reported [108]. Related toxins containing  
57–60 amino acid residues and cross-linked by three disulfide bridges were subsequently characterized 
from different mamba venoms and eventually named dendrotoxins (DTXs), such as the α-dendrotoxin 
from the green mamba snake (Dendroaspis angusticeps) [95,109]. Dendrotoxins are potent blockers of 
certain subtypes of voltage-gated potassium channels (Table 2) [95,110]. Differently from toxins I  
and K, dendrotoxin E, from black mamba, was shown to inhibit both trypsin and chymotrypsin  
(Table 1) [48].  
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Also from Dendroaspis angusticeps, calcicludine (CaC, UniProtKB P81658) is a 60-amino acid 





modulator activities. CaC specifically blocks most of the high-threshold Ca
2+
 channels in the 
nanomolar range, specially the L-type component of the Ca
2+
 current [111,112]. β-Bungarotoxin was 
previously isolated from Bungarus multicinctus venom and comprises two dissimilar polypeptide 
chains, the A chain (~14 kDa) and B chain (~7 kDa), which are linked by an interchain disulfide 
bridge [113]. The B chain of β-bungarotoxin is homologous to venom basic protease inhibitors but, 
similar to most of dendrotoxins, displays no protease inhibitory activity and also blocks voltage-gated 
K
+
 channels [114]. 
Despite the dendrotoxin related toxins, several Kunitz-type protease inhibitors have been isolated 
from snake venoms, particularly from Elapidae and Viperidae snakes. The Russell’s viper venom 
(RVV) inhibitor, from Daboia russelii (=Vipera russelli), seems to be the first of them [101]. It is  
a basic polypeptide with deduced 60 amino acid residues and inhibitory activity against plasma and 
pancreatic kallikreins, plasmin and trypsin, being more potent against trypsin. A Kunitz-type inhibitor 
homolog (RVV inhibitor II, UniProtKB P00990) was further sequenced from the venom of the Eastern 
Russel’s viper (=Daboia siamensis) [115]. Recently, similar polypeptides were identified in the venom 
of Daboia siamensis [49,50]. From the Burmese specie, BBPTI-1 (Table 1) was shown to strongly 
inhibit chymotrypsin activity, with no detectable inhibitory activity against trypsin [49]. From the 
Chinese one, two trypsin inhibitors (CBPTI-1 and CBPTI-2, Table 1) and one chymotrypsin inhibitor 
(CBPTI-3, Table 1) were purified and cloned [50]. 
Five PIs were isolated from the venoms of the African Elapids Hemachatus haemachatus and  
Naja nivea [51]. The isolated trypsin inhibitors have 52 to 57 amino acid residues, and were all devoid 
of tryptophan. Except for one peptide from Naja nivea venom, designated NNV inhibitor la, which had 
two disulfide bonds, all the others contained three. Two high homologous peptides (HHV inhibitor II 
and NNV inhibitor II, Table 1) were completely sequenced. Similar to HHV inhibitor I, HHV inhibitor 
II was active against trypsin, α-chymotrypsin, plasma kallikreins and plasmin from bovine sources. 
NNV inhibitor II was only tested against trypsin. 
From the venom of the long-nosed viper Vipera ammodytes, three basic PIs were isolated [52].  
Two of them strongly inhibit trypsin, whereas the third one primarily inhibits chymotrypsin (Table 1). 
Other enzymes were also inhibited, although with lower potency. The precursors of the chymotrypsin 
inhibitor and trypsin inhibitor I were further obtained [116]. An homologous putative trypsin inhibitor 
was also sequenced from the venom of the leaf-nosed viper, Eristicophis macmahoni (UniProtKB 
P24541) [117]. 
Until now, two PIs have been isolated from Bungarus fasciatus venom [54,55]. The first of them 
was denoted protease inhibitor IX (or BF9, Table 1) and consists of a polypeptide chain of  
65 amino acid residues that, when cleaved, generates the protease inhibitor VIIIb [54]. BF9 
specifically inhibits α-chymotrypsin in a 1:1 molar ratio and is structurally similar to the Kunitz-type 
toxins [54,118]. The second is a Kunitz-type serine protease inhibitor named bungaruskunin (Table 1), 
which was characterized from venom and also cloned from venom glands [55]. The predicted 
precursor contains 83 amino acid residues, including a 24-residues long signal peptide. The mature 
bungaruskunin inhibits trypsin, chymotrypsin, and elastase, but not thrombin.  
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From the venom of the cobra Naja naja, a strong trypsin inhibitor (Table 1) [56] and a putative  
57-amino acid residue chymotrypsin inhibitor (UniProtKB P19859) were characterized [119]. With 
almost 90% identity to the latter, a chymotrypsin inhibitor was also characterized from the venom of 
Naja atra (NACI, Table 1) [57]. No detectable inhibitory effects were observed on trypsin or plasmin. 
Its precursor was further characterized and it was shown that the expressed protein without the first 
three residues at its N-terminal led to a moderate increase in the inhibitory constant against 
chymotrypsin [58]. 
A weak chymotrypsin inhibitor with no inhibitory action against trypsin was characterized from the 
venom of the king cobra Ophiophagus hannah (Oh11-1, Table 1) [59]. After that, a peptide named 
OH-TCI was shown to inhibit both chymotrypsin and trypsin with similar potencies [60]. The 
inhibition constants of the native peptide for chymotrypsin and trypsin were both around 170 nM, 
while the recombinant peptide presented no more than 5-fold difference between both values (Table 1). 
No detectable effects were observed against thrombin and subtilisin [60]. 
The structural organization of the genes encoding three protease inhibitor-like proteins (PILP-1 to 
PILP-3) from Bungarus multicinctus was reported [61]. Recombinant PILP-1 inhibited trypsin  
(Table 1), whereas PILP-2 (UniProtKB B4ESA3) and PILP-3 (UniProtKB B4ESA4) did not inhibit 
chymotrypsin or trypsin. PILP genes share identical organization with B chain genes, with three exons 
interrupted by two introns in similar positions. Comparative analysis of PILP and B chain genes, 
together with the high degree of sequence similarity of the polypeptides, suggested that these genes 
have originated from a common ancestor and that they should be evolved by gene duplication followed 
by divergence [61].  
Two distinct types of KTTs have already been characterized from the venom of Australian elapid 
snakes. Taicatoxin serine protease inhibitor (TSPI, Table 1) was purified from the venom of 
Oxyuranus scutellatus scutellatus as part of a multimeric complex that blocks high threshold calcium 




 channels [62,120]. In its isolated form, TSPI 
exhibits antifibrinolytic activity and is a broad spectrum inhibitor, being active against plasma and 
tissue kallikrein, trypsin, elastase, factor Xa, and α-factor XIIa [62,63]. Subsequently, a second family 
of Kunitz-type inhibitors was purified, cloned and characterized from the venom of the common 
brown snake Pseudonaja textilis [7,121]. Two of them, textilinin-1 and -2 (Table 1), were shown to be 
potent plasmin inhibitors [7,63]. Textilinin-1 is also a potent trypsin inhibitor, with little effect on both 
plasma and tissue kallikrein, and no effect on many other proteases tested [63,122]. Because textilin-1 
has been shown to inhibit plasmin and reduce bleeding in a small animal model [7], further studies 
have suggested its use as a therapeutic alternative for aprotinin [122,123], which is widely used in 
surgery as an anti-bleeding agent but is associated with numerous side effects [124]. 
From the New Guinean Pseudechis australis (=Pseudechis rossignolii), three cDNAs encoding 
Kunitz-type protease inhibitors were isolated and named Pr-mulgins 1, 2 and 3 [65]. The putative 
polypeptides are 92.4%–99.3% identical with their orthologs in the Australian Pseudechis australis [125]. 
Recombinant Pr-mulgin 1 significantly affected matrix metalloprotease (MMP) 2; Pr-mulgin 2 and 3 
strongly inhibited trypsin and plasma plasmin; and Pr-mulgin 2 also inhibited α-chymotrypsin (Table 1). 
No inhibitory effects were observed against other proteases such as serine proteases (elastase, 
kallikrein and pepsin), cysteine protease (cathepsin G), and MMPs (1,3,7,8,9,10,12,13 and 14). These 
peptides did not block Drosophila K
+
 channels (Shaker) and rat K
+
 channels (Kv1.1). 
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Recently, a trypsin inhibitor named PIVL (Table 1) was characterized from the venom of the 
Tunisian snake Macrovipera lebetina transmediterranea [64]. Besides trypsin inhibitory activity, 
PIVL also exhibits anti-tumor effect and displays integrin inhibitory activity without being cytotoxic. 
No inhibitory effect was detected on chymotrypsin.  
Transcriptomic approaches are also showing numerous serine PIs in snake venoms. Transcriptome 
of the venom glands of the Australian elapid snake Drysdalia coronoides revealed that serine protease 
inhibitors are one of the major components from this venom [126]. The presence of putative  
Kunitz-type inhibitors was also shown in the venom gland transcriptomes of the elapid snakes 
Bungarus multicinctus and Naja atra [127], of the viper snake Vipera nikolskii [128], of the Brazilian 
coral snake Micrurus altirostris [129], and from several Australian elapid snakes [125]. 
Other classes of PIs in snake venoms comprise the cystatins and the bradykinin-potentiating 
peptides (BPPs). The cystatins are a family of cysteine protease inhibitors with homology to chicken 
cystatin/ovocystatin and human cystatin C [130]. To date, few snake venom cystatins have been fully 
characterized, and some of them were shown to inhibit papain-like cysteine proteases [131–134]. BPPs 
consist of about 5–14 amino acid residues that specifically block the endothelial metalloprotease 
angiotensin I-converting enzyme (ACE). The first report of a “bradykinin-potentiating factor (BPF)”  
in the venom of Bothrops jararaca was in 1965 [135]. These factors were subsequently purified and 
characterized as peptides responsible for potentiating the activity of bradykinin and inhibition of  
ACE [136,137]. Among a series of analogs of BPPs studied, one of them was modified to produce 
captopril, an orally available peptidomimetic that, together with further modified molecules, become 
widely used for the treatment of hypertension [138]. Although not presented in detail in this review, 
other BPPs have been identified in snake venoms or venoms glands [139–143]. 
4.2. PIs from Scorpion Venoms 
The first report on a protease inhibitor from scorpion venom was made in 1981 by Chhatwal and 
Habermann [66]. The peptide was purified from the venom of the Indian red scorpion  
Mesobuthus tamulus and consisted of 77 amino acid residues and 8500 Da (Table 1). It inhibited 
trypsin and also kallikrein, but had weak or no activity against chymotrypsin, plasmin and  
thrombin [66]. Its sequence, however, was not revealed.  
Posteriorly, Schwartz and collaborators [67] reported for the first time, by means of transcriptomic 
analysis, the presence of a Kunitz type precursor in scorpions. The mature peptide, named Hg1, from 
the Mexican scorpion Hadrurus gertschi, was not found in the venom and its activity remained 
unknown, until it was recently expressed by Escherichia coli BL21(DE3) cells, purified and tested [68]. 
Together with Hg1, other six recombinant scorpion peptides (LmKTT-1a, LmKTT-1b, LmKTT-1c, 
BmKTT-1, BmKTT-2 and BmKTT-3) were also characterized as trypsin inhibitors (Table 1), with no 
activity against chymotrypsin or elastase even at high doses [68]. Among them, recombinant Hg1 
presented the lowest dissociation constant against trypsin, while rBmKTT-3, from Mesobuthus 
martensii, had the highest [68]. LmKTT-1b, also named SdPI, from Lychas mucronatus, was the first 
functionally characterized Kunitz-type peptide from scorpion [16]. All these seven recombinant 
peptides seem to have similar secondary structure to BPTI, as analyzed by circular dichroism 
spectroscopy [68]. Moreover, some of them are also blockers of potassium channels (Table 2) [68]. 
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From the cDNA libraries constructed from the venom glands of three scorpion species,  
four putative serine protease inhibitors belonging to the Ascaris-type peptides were recently identified: 
SjAPI (Scorpiops jendeki Ascaris-type protease inhibitor), SjAPI-2 (Scorpiops jendeki Ascaris-type 
protease inhibitor 2), CtAPI (Chaerilus tricostatus Ascaris-type protease inhibitor), and BmAPI 
(Buthus martensii Ascaris-type protease inhibitor) [69]. Members of the Ascaris-type peptides’ family 
are characterized by the presence of five disulfide bonds [144]. The recombinant SjAPI (Table 1) 
inhibited both α-chymotrypsin and elastase, with no detectable effect on trypsin. SjAPI is produced as 
a precursor polypeptide of 94 amino acid residues, which includes a signal peptide of 24 residues,  
a propeptide of 6 residues, and a 64-residue mature peptide [69].  
Besides these serine protease inhibitors, a plasmin inhibitor named discreplasminin was isolated 
from Tityus discrepans scorpion venom. It has an antifibrinolytic mechanism similar to aprotinin and 
probably interacts with the active sites of plasmin and tPA, a tissue-type plasminogen activator [145]. 
Moreover, a putative serpin peptidase inhibitor-like protein (UniProtKB C5J8C1) was identified in the 
cDNA venom gland library of Opisthacanthus cayaporum. However, it is composed by 176 encoded 
amino acid residues and lacks the signal peptide region [146]. 
4.3. PIs from Spider Venoms 
Yuan and collaborators reported the first superfamily of Kunitz-type toxins from spiders [14]. It is 
composed by HWTX-XI, the prototype member of this superfamily, and 45 additional putative KTTs, 
which were found by means of two venom gland cDNA libraries constructions of the two Chinese bird 
spiders Ornithoctonus huwena and O. haiana (34 and 11 putative KTTs, respectively). HWTX-XI 
(Table 1) has 6166.23 Da and six cysteine residues. It was isolated from both venom and venom gland 
extract of O. huwena. HWTX-XI inhibits trypsin stoichiometrically in a 1:1 ratio and strongly binds to 
trypsin, while presenting lower affinity to α-chymotrypsin. It had about 30-fold higher inhibition 
potential to trypsin compared with BPTI, with a Kd value of 2.3 × 10
−10
 M, while BPTI had a Kd of 
6.57 × 10
−9
 M under the same experimental conditions [14]. Similar to many KTTs, HWTX-XI also 
inhibits potassium channel currents (Table 2). 
After that, a putative serine protease inhibitor was revealed from the cDNA library of  
Loxosceles intermedia venom gland [147]. This single EST (cluster LIS209) presented high similarity 
with serine protease inhibitors from mammals, such as Mus musculus (UniProtKB O35684) and  
Pan troglodytes, and also from Ambliomma americanum tick.  
Recently, the first spider Kunitz-type inhibitor with plasmin and elastase inhibitory activity 
(AvKTI, Table 1) was identified in Araneus ventricosus [70]. However, its coding clone was selected 
from the expressed sequence tags (ESTs) that were generated from a cDNA library constructed using  
A. ventricosus whole bodies. Because AvKTI is expressed only in the epidermis, it is suggested that it 
is a Kunitz-type inhibitor derived from the spider body, but not from venom [70]. Recombinant AvKTI 
inhibited both trypsin and chymotrypsin, with no detectable inhibitory effects on factor Xa, thrombin 
or tissue plasminogen activator (tPA). However, it inhibited plasmin and neutrophil elastase [70]. 
Thus, among the proteases tested, the most prominent inhibitory effect of AvKTI was observed on 
plasmin, resembling other PIs with antifibrinolytic activity, such as scorpion discreplasminin [145] and 
snake textilinins [7,122]. In addition, another Kunitz-type inhibitor (AvCI, Table 1) was obtained from  
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A. ventricosus in a similar manner to AvKTI [71]. AvCI inhibits chymotrypsin, the microbial serine 
proteases subtilisin A and proteinase K, and also the human neutrophil elastase and porcine pancreatic 
elastase. It was ineffective against trypsin, factor Xa, thrombin, tPA and plasmin [71]. 
4.4. PIs from the Skin Secretion of Anurans 
The skin granular glands of Anurans (frogs and toads) produce a remarkably diverse range of 
bioactive polypeptides [17]. Among them, almost all the serine protease inhibitors from amphibians 
contain 3–5 conserved disulfide bridges, with few exceptions [85–87], and their biological role is still 
not clear [87]. Unless otherwise stated, all amphibian PIs described in this section were obtained from 
their skin secretions. 
From the toad Bombina bombina, a 60-residue polypeptide cross-linked by five disulfide bridges 
was isolated and cloned [72]. Named BSTI, it inhibits both porcine trypsin and human thrombin  
(Table 1), with no activity against chymotrypsin. Its precursor contains 84 amino acid residues, 
including a 24-residue signal peptide [72]. Structurally homologous to BSTI, a trypsin inhibitor named 
BMTI (Table 1) was characterized from the toad Bombina maxima [73]. Its precursor also contains  
84 amino acid residues, with a putative signal peptide of 24 residues. Unlike BSTI, BMTI had  
no inhibitory effect on thrombin. Chymotrypsin, elastase and bacterial subtilisin were also not 
inhibited at up to 10 µM concentration. Also with five disulfide bridges, a weak trypsin inhibitor was 
isolated from the frog Rana areolata (Table 1) [74]. 
In addition, two trypsin inhibitor analogs (BOTI and BVTI) were isolated from the toads  
Bombina orientalis and Bombina variegata (Table 1) [75]. By means of a new non-invasive technique, 
two cDNA libraries were constructed from the dermal venom of these two species and both precursors 
were obtained, which contain 84 amino acid residues, including a 24-residue signal peptide. The 
trypsin inhibitory activity of BOTI and BVTI was not measured [75].  
From the toad Bombina microdeladigitora, two serine protease inhibitors structurally homologous 
to BSTI were identified (BMSI 1 and BMSI 2, Table 1) [76]. BMSI 1 inhibits both trypsin and 
thrombin. No inhibition of the hydrolysis of substrates by elastase, chymotrypsin and subtilisin were 
observed with an inhibitor concentration up to 10 µM. 
From Hyla simplex, two serine protease inhibitors were isolated (Table 1)—an alpha-1-antitrypsin-like 
serpin (hylaserpin-S1) and a wasp venom-like toxin (hylaserpin-S2) [77]. Hylaserpin-S2 precursor is 
composed by 83 amino acid residues, including a predicted signal peptide of 27 residues. It is 
structurally related to those amphibian serine protease inhibitors containing five disulfide bridges from 
Bombina and Rana genera [72–75]. Hylaserpin-S1 is a much longer peptide, with 44 kDa, and is 
encoded by a 415-amino acid residues precursor, with a signal peptide of 23 amino acid residues. 
Hylaserpin-S1 inhibited both trypsin and chymotrypsin, whereas hylaserpin-S2 only inhibited trypsin, 
similarly to BSTI [72,77]. Moreover, hylaserpin-S2 had bacteriostatic effect against Gram-positive 
bacteria Bacillus subtilis, and hylaserpin-S1 displayed direct microorganism-killing abilities against  
B. subtilis, E. coli, and Candida albicans [77]. 
Another long protease inhibitor, consisting of a basic single chain glycoprotein with about 22 kDa, 
was isolated from the toad Bufo andrewsi (BATI, Table 1). BATI inhibits trypsin, but displays  
no inhibitory activity against chymotrypsin, thrombin and elastase [78]. Also from Bufo andrewsi,  
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an irreversible serine protease inhibitor (baserpin, Table 1) also consisting of a single chain 
glycoprotein with ~60 kDa was purified. Baserpin, which possibly belongs to the serpin superfamily, 
inhibits the catalytic activity of trypsin, chymotrypsin and elastase, with no detectable inhibitory 
effects on thrombin [79]. Similar to BATI, the peptide KPHTI (Table 1), from the frog  
Kaloula pulchra hainana, is a single chain glycoprotein with about 23 kDa, and also inhibits trypsin, 
but not chymotrypsin, thrombin, elastase or subtilisin [80]. Only few N-terminal residues from BATI, 
baserpin and KPHTI were sequenced [78–80]. 
An albumin-like protein with approximately 60 kDa (albumin-1, UniProtKB Q3T479) was isolated 
and cloned from Bombina maxima skin [148]. Purified from skin homogenate, this protein inhibits 
trypsin (Kd of 1.92 nM), with no inhibition against thrombin, chymotrypsin, elastase or subtilisin. 
However, this protein, which shares similar biochemical and immunochemical properties as those of 
the B. maxima serum albumin, was not detected in the skin secretions [148].  
Two peptides analogous to the Kazal family of serine protease inhibitors were obtained from the 
skin extract of Phyllomedusa sauvagii (PSKP-1 and PSKP-2, Table 1) [81]. Recombinant PSKP-1 
inhibited a serum prolyl endopeptidase from blood serum, but was not active against trypsin, chymotrypsin, 
V8 protease or proteinase K. In addition, PSKP-1 displays bactericidal activity and induces agglutination 
of red cells and bacteria [81]. Similar to these peptides, two putative protease inhibitors (PI01 and 
PI02) were obtained from the cDNA library of Phyllomedusa nordestina (Table 1). The third of them 
(PI03) is shorter and structurally different [82]. A different Kazal-type protein with potent trypsin 
inhibitory activity (ACKTI, Table 1) was characterized from the frog Agalychnis callidryas [83]. Its 
precursor contains 78 amino acid residues, including a signal peptide with 26 residues. 
A Kunitz-type protease inhibitor (Table 1) was isolated from the skin secretion of the tomato frog 
Dyscophus guineti [17]. It contains 57 amino acid residues, including six cysteine residues, and 
inhibits trypsin. In addition, a chymotrypsin inhibitor of Kunitz-type (KSCI, Table 1) was characterized 
from Kassina senegalensis [84]. Its precursor sequence contains 84 amino acid residues, including a 
22-residue putative signal peptide. 
From the frog Hyla annectans, a different Kunitz-type inhibitor peptide (anntoxin, Table 1)  
with additional (although weak) sodium channel activity was characterized [85]. It inhibits 
tetrodotoxin-sensitive (TTX-S) sodium channel currents elicited from adult rat dorsal root ganglion 
neurons with an IC50 value of 3.4 µM, and is also lethal to different potential predators, like insects, 
snake, birds, and mice. Calcium and potassium currents were few or not inhibited even at 
concentrations up to 10 µM. Anntoxin inhibits trypsin and is homologous to KTTs, but contains only 
two of the three highly conserved disulfide bridges [85].  
The first small serine protease inhibitor known to contain only a single disulfide bond characterized 
from animals was isolated and cloned from the skin secretion of the frog Odorrana grahami [86]. Five 
different precursors, although highly conserved, encode OGTI. All of them contain 70 amino acid 
residues including a signal peptide of 22 residues, an acidic spacer peptide with 31 residues and equal 
mature peptides with 17 residues. OGTI toxin inhibited trypsin (Table 1), but had no inhibitory effects 
on thrombin, chymotrypsin, elastase, subtilisin, plasmin or furin at concentrations up to 10 µM [86]. 
Similar precursors encoding mature peptides equal to OGTI seem to have been found in the skin 
secretions of Odorrana andersonii (UniProtKB E3SZL1), Odorrana margaretae (UniProtKB 
E1AWD0) and Rana schmackeri (UniProtKB D5LXG2). 
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Another small peptide with only one disulfide bond (HV-BBI, Table 1) was characterized from the 
frog Huia versabilis (=Odorrana versabilis) [87]. This Bowman-Birk type protease inhibitor is 
encoded by a precursor of 62 amino acid residues, including a 22-residue signal peptide, a 22-residue 
propeptide, and a mature peptide consisting of 18 amino acid residues and a C-terminal amidation.  
The synthetic peptide was found to behave as a competitive reversible inhibitor of trypsin.  
No chymotrypsin inhibitory activity was observed [87]. 
4.5. PIs from Hymenopterans’ Venoms 
There are few reports on serine protease inhibitors from the venom of Hymenopterans, such as 
wasps and bees. Moreover, some of them are putative PIs, obtained by means of transcriptomic tools, 
and have not been tested yet.  
From the venom of the solitary spider wasp Anoplius samariensis, a peptide named As-fr-19 
(UniProtKB Q589G4) was purified and cloned [149]. Its precursor encodes a peptide with 75 amino 
acid residues, containing a signal peptide of 17 residues and a mature toxin of 58 residues. As-fr-19 
contains six cysteine residues and presents sequence similarity to some sea anemone and snake toxins, 
such as the kalicludines from Anemonia sulcata [27] and snake dendrotoxin I and K and  
calciludine [108,111]. Thus, As-fr-19 may exert inhibitory effects on serine proteases and on 
potassium and/or calcium channels [149]. 
Using random sequencing analysis, novel putative toxins from the venom of the parasitoid wasp 
Pimpla hypochondriaca have been sequenced [150]. Among the cysteine-rich venom proteins, four of 
them (cvp1, cvp2, cvp4 and cvp6) presented sequence similarity with protease inhibitors. Both cvp1 
and cvp6 contain 10 cysteine residues and are similar to the chymotrypsin inhibitor AMCI 1 from the 
larval hemolymph of Apis mellifera (UniProtKB P56682). Mature cvp2 shares high sequence 
similarity to Kunitz-type serine protease inhibitors, and cvp4 consists of a three times repeated  
six cysteine motif and is similar to pacifastin, a protease inhibitor from locust (UniProtKB Q8WQ22).  
A serine protease inhibitor polypeptide named bicolin (Table 1) was characterized from the venom 
of the wasp Vespa bicolor Fabricius [88]. Its precursor is composed of 77 amino acid residues 
comprising a 23-residue predicted signal peptide and the 54-residue mature toxin cross-linked by three 
disulfide bonds. Bicolin is homologous to As-fr-19 and cvp2 and showed inhibitory activity against 
trypsin and thrombin, but had no effect on elastase and chymotrypsin. Bicolin was found to own 
anticoagulation function, possibly due to its thrombin-inhibitory activity [88]. 
From Bombus ignitus bumblebee venom, a Kunitz-type serine protease inhibitor (Bi-KTI, Table 1) 
with plasmin inhibitory activity was characterized [6]. Its precursor consists of 82 amino acid residues, 
with a predicted 24-residue signal peptide and a 58-residue mature peptide, including six cysteine 
residues. It strongly inhibits plasmin, although its inhibitory activity was approximately two-fold 
weaker than that of aprotinin. Bi-KTI did not inhibit other enzymes from the hemostatic system, such 
as factor Xa, thrombin, or tPA. These results are similar to those of snake textilinins [7,122]. Bi-KTI, 
which acts as an antifibrinolytic agent, and Bi-VSP, a Bombus ignitus venom serine protease 
previously characterized that acts as a fibrin(ogen)olytic agent [151], may act in a cooperative fashion 
to promote the spread of bee venom under anti-bleeding conditions [6]. 
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Similar results were obtained with the Kunitz-type inhibitor Bt-KTI (Table 1), from  
Bombus terrestris bumblebee venom [89]. Bt-KTI shares high sequence similarity to Bi-KTI and also 
consists of a 58-amino acid residue mature peptide, including six conserved cysteine residues. 
Moreover, it displays strong inhibitory activity against plasmin, exhibiting an antifibrinolytic activity, 
and does not inhibit factor Xa, thrombin or tPA [89]. 
From a cDNA library constructed using Asiatic honeybee (Apis cerana) whole bodies, a putative 
chymotrypsin inhibitor (AcCI) with ten conserved disulfide bridges was identified [152]. Based on the 
RT-PCR done with samples of epidermis, fat body, midgut, and venom gland, the AcCI gene was 
found to be constitutively expressed in all of these tissues. The recombinant AcCI (rAcCI), obtained 
by a baculovirus/insect cell expression system, inhibited the activity of chymotrypsin (IC50: 24.71 nM), 
with an inhibitory constant (Ki) of 11.27 nM, and of human neutrophil (IC50: 38.50 nM) and porcine 
pancreatic (IC50: 70.21 nM) elastases, with Ki values of 61.05 nM and 101.89 nM, respectively. rAcCI 
had no inhibitory activity against trypsin, factor Xa, thrombin, tPA, or plasmin. It is worthy to mention 
that although AcCI precursor codes to a 65-amino acid residue mature peptide, with a predicted 
molecular mass of 7.2 kDa, rAcCI was identified as a 16-kDa protein, which was interpreted by 
authors as due to the presence of carbohydrate moieties [152]. 
5. PIs and Potassium Channel Activity  
It is suggested that the evolution process of Kunitz-type toxins has probably three stages: old 
functional molecules, bi-functional toxins and new function toxins [14]. Thus, some Kunitz-type 
protease inhibitors could acquire the neurotoxin function, whereas others would even lose their 
protease inhibitory role and act on voltage-gated ion channels [14,116]. Potent and specific neurotoxic 
K
+
 channel blockers with Kunitz-type motif are particularly developed in snakes, while sea anemone, 
scorpion and spider toxins have developed only the dual-functional KTTs, frequently with weak K
+
 
channel blocking activity. One possible explanation is that the selective pressure would have act in 
order to keep the dual-functional KTTs with weak K
+
 channel blocking activity in these latter animals, 
which already have other potent neurotoxins in their venoms/body extracts. By contrast, only K
+
 
channel blockers presenting the Kunitz-type motif were characterized from snake venoms so far [14].  
Typical examples of this are the snake dendrotoxins. Although being similar to Kunitz-type 
protease inhibitors in amino acid sequences and three-dimensional conformation [153], dendrotoxins 
display few or no serine protease inhibitory activity. By contrast, they are strong blockers of potassium 
channels (Table 2) [95,110]. Both dendrotoxin (or α-dendrotoxin, UniProtKB P00980) from green 
mamba Dendroaspis angusticeps and toxin I (UniProtKB P00979), from the black mamba 
Dendroaspis polylepis, block cloned Kv1.1, Kv1.2 and Kv1.6 channels in the low nanomolar range  
(Kd < 20 nM) [95,154]. Toxin K (UniProtKB P00981), also from the black mamba D. polylepis, 
preferentially blocks Kv1.1 channels and is active at picomolar concentrations [96,155]. Other 
subtypes of potassium channels are also blocked by some dendrotoxins, although with lower  
affinity [95]. The protein E homologues from green mamba venom are also able to block Kv1.1 
channels expressed in oocytes, although higher concentrations are needed (Table 2) [98]. Named 
“DaE1” and “DaE2”, these polypeptides share 98% and 95% identity, respectively, to trypsin inhibitor 
E from black mamba venom [156]. 
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By means of chemical modifications of native dendrotoxins and genetic engineering to produce 
mutated toxins, the amino acid residues that are essential for their interaction with potassium channels 
have been identified [95,110]. Lys5 seems to be the major determinant of the binding affinity of  
α-DTX and DTX-I for K+ channels (Figure 1) [157,158]. Along with it, the neighbor hydrophobic 
residue Leu9 is also important for binding to K
+
 channels [159]. Lys19, which is around the  
“anti-protease” site, caused only a little loss of activity when acetylated in DTX-I [158] or replaced by 
Ala in α-DTX [159].  
Besides Lys5, or the equivalent Lys3 in DTX-K, the amino acids at the β-turn region  
(residues 24–28 in toxin K, in particular Trp25 and Lys26) are responsible for the potassium channel 
activity [160,161]. In DTX-I, acetylation of Lys29 inactivated the toxin, possibly by producing large 
structural perturbations [158]. Moreover, although acetylation of Lys28 alone had little effect, the 
toxin became almost inactive when both Lys28 and Tyr24 were modified [158]. Differently, in α-DTX, 
modification of the Lys triplet 28–30 to Ala-Ala-Gly exhibited only small decreases in biological 
activity [162]. Seven amino acid residues (Lys3, Tyr4, Lys6, Leu7, Pro8, Arg10 and Lys26) from  
δ-dendrotoxin were shown to be important for the toxin’s interaction with a Shaker channel  
variant [163].  
The heterodimeric snake neurotoxin β-bungarotoxin inhibits the release of acetylcholine from motor 
nerve endings [164]. It consists of a PLA2 subunit and a K
+
 channel binding subunit, which is  
a member of the Kunitz-type protease-inhibitor superfamily, both linked by a disulfide bridge [165].  
β-Bungarotoxin acts on a presynaptic potassium channel and then, with the phospholipase A2 unit 
activity, blocks neurotransmission, altering the acetylcholine release [166]. β-Bungarotoxin (2 µM/L) 
partially blocked fast K
+
 outward current (IK.F) through the fast K
+









 channel in motor nerve terminals of snake [167]. The 
mutated B(C55S)-bungarotoxin chain, where Cys55 was replaced by Ser55, at 200 nM, blocked the 
outward K
+
 current through synaptosomal membranes. However, the B chain is not the only essential 
subunit for the binding of β-bungarotoxin to its target given that it has been shown that Ca2+ is required 
for the binding of β-bungarotoxin with its receptors [168] and that the A chain is the Ca2+-binding 
subunit of the toxin [169]. 
Some dendrotoxin homologues have been characterized in other venomous animals, such as sea 
anemones, cone snails, scorpions and spiders (Figure 1 and Table 2), raising the possibility that the 
protease inhibitor structural framework has been used to create potassium channel blocking activity, 
being the new active site different from and independent of the old one [14]. 
Figure 1. Representative alignment of toxins with the Kunitz-type motif from venomous 
animals. Organisms from which the polypeptides were obtained are indicated by the 
colored lines at left: blue, sea anemones; grey, snakes; red, scorpions; yellow, spider; 
green, Anurans; purple, Hymenopterans; black, cone snail. The toxins that present 
potassium channel blocking activity are indicated by symbols after their names:  
●, K+ channel blockers with no protease inhibitory activity or still not tested against 
proteases; ♦ and ◊, dual-function toxins, where ♦ denotes toxins with stronger potency in 
K
+
 channels than those indicated by ◊. The other polypeptides, without symbols, are all 
serine protease inhibitors. The alignment was generated by ClustalW [170] and the 
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consensus sequence was colored using Chroma and manual edition [171]. Key residues for 
K
+
 channel blocking activity are highlighted in red. Key residues for protease inhibition 
with more specificity to trypsin or chymotrypsin are highlighted in magenta and cyan, 
respectively. Some of them were suggested to be key residues by sequence similarity with 
other toxins. The P1 site residues are pointed by an arrow. Capital letters denote amino 
acids. Lower-case letters denote: b, big; p, polar; h, hydrophobic; a, aromatic. The known 
conserved disulfide bridges are labeled in black lines. The black dotted line suggests a 
possible new disulfide bridge in scorpion venom PIs [99]. The numbers within parenthesis 
mean amino acid residues from the C-terminus of the peptides that were not completely 
shown in this alignment. 
 
The kalicludines AsKC1, AsKC2 and AsKC3, from the sea anemone Anemonia sulcata, were 
shown to inhibit the binding of 
125
I-α-dendrotoxin to rat brain membranes in a competitive way, with 
Mar. Drugs 2013, 11 2089 
 
 
IC50 values of 375 nM for AsKC1 and 500 nM for AsKC3. AsKC2 had an inhibition constant Ki of  
20 nM. All these toxins were able to inhibit Kv1.2 channels expressed in Xenopus oocytes  
(Table 2) [27]. Similarly, SHTX-3, from the sea anemone Stichodactyla haddoni, inhibited the binding 
of 
125
I-α-dendrotoxin to rat synaptosomal membranes [40]. Its IC50 value (Table 2) indicated that this 
toxin is about 110 times less potent than α-dendrotoxin, which under the same conditions presented  
an estimated IC50 value of 5.7 nM. 
The sea anemone peptide APEKTx1, from A. elegantissima, was subject to a wide screening on  
23 ion channels expressed in Xenopus laevis oocytes: 13 cloned voltage-gated K
+
 channels  
(Kv1.1–Kv1.6, Kv1.1 triple mutant, Kv2.1, Kv3.1, Kv4.2, Kv4.3, hERG, the insect channel Shaker IR);  
2 cloned hyperpolarization-activated cyclic nucleotide-sensitive Ca
2+
 non-selective channels (HCN1 
and HCN2) and 8 cloned voltage-gated Na
+
 channels (Nav1.2–Nav1.8 and the insect channel  
DmNav1) [42]. With exception of Kv1.1 channel, no significant effects could be observed on the other 
ion channel isoforms at concentrations up to 1 µM. The IC50 value for Kv1.1 channel (Table 2) 
indicated that APETx1 inhibits Kv1.1 channels with the same potency as DTX-I and α-DTX. The 
inhibition of Kv1.1 channels by this toxin is reversible and not voltage-dependent. APETx1 did not 
alter channel gating and it presumably acts by blocking the pore in the open state of the Kv channel. It 
is suggested that APEKTx1 acts on the channel’s extracellular site [42]. 
It was investigated whether the sensitivity of APEKTx1 for Kv1.1 channels could be affected by 
mutating 3 amino acid residues (A352P, E353S and Y379H) in the dendrotoxin binding site, which is 
located in the H5 loop between the transmembrane domains S5 and S6 of Kv1.1 α-subunit. By doing 
these mutations, the pore region of this triple mutant closely resembles the one of Kv1.3 channels. 
Even at 100 µM concentration, APEKTx1 only induced 53% current inhibition at the mutated channel, 
yielding an IC50 value of 10.8 ± 0.6 µM, highlighting the crucial interaction of these channel residues 
with the toxin. The same experiment was performed with DTX-K and it was obtained an IC50 value of 
0.51 ± 0.064 µM for wild-type Kv1.1 channels and 5.28 ± 0.23 µM for the triple mutant channel, 
which represents a 10-fold decrease in sensitivity [42].  
Despite the high sequence similarity between InhVJ toxin, from the sea anemone A. sulcata, and 
these other sea anemone polypeptides (up to 50%), InhVJ did not modified potassium channel currents 
(Kv1.1–Kv1.6, Shaker, Kv2.1, Kv3.1, Kv4.2, Kv4.3 and cardiac hERG channel) expressed in  
Xenopus oocytes in a concentration range of up to 50 µM [47]. This inactivity was attributed mainly to 
the absence of a functional dyad consisting of basic and hydrophobic amino acid residues in the 
structure of InhVJ. In addition, it was suggested that the small positive charge (+0.02) of InhVJ was 
apparently not enough to inhibit Kv channels, since heavily charged polypeptides would interact better 
with the negative electrostatic potential of the extracellular part of potassium channels [47].  
Recombinant conkunitzin-S1, from the cone snail Conus striatus, was shown to inhibit the  
Shaker potassium channel expressed in Xenopus oocytes (Table 2) [94,105]. Conkunitzin-S1presented 
high affinity for mutated K427D Shaker-Δ6-46 channels, with an IC50 value that was in good 
agreement to that of Conk-S1 obtained from natural source [94].  
All seven scorpion protease inhibitors described by Chen and collaborators [68] were tested on 
Kv1.3 channels (Table 2). The toxins rLmKTT-1a, rLmKTT-1b and rLmKTT-1c inhibited ~50% of 
Kv1.3 channel currents at 1 µM concentration, whereas rHg1, rBmKTT-1 and rBmKTT-2 promoted 
~60%–80% current inhibition at the same concentration. rHg1 was also active at 100 nM concentration, 
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and rBmKTT-3 had only a weak effect on Kv1.3 channel currents. rHg1 was also shown to inhibit 
<50% of the Kv1.1 and Kv1.2 channel currents, with little effect on SKCa3 and BKCa channel currents, 
all at 1 µM concentration. These results indicate that Hg1 is specific for Kv1.3 channels [68].  
Different Hg1 mutants (generated by the alanine-scanning strategy) were tested on Kv1.3  
channels [68], showing no apparent effects of His2, His3, Asn4, Arg5, Leu9 and Lys13 residues on the 
pharmacological activity of the toxin. Since basic amino acid residues from animal toxins are usually 
essential for the potassium channel blocking activity [172,173], mutations were performed on the 
second cluster of basic residues of Hg1, located at the C-terminus of the toxin. Replacement of Lys56, 
Arg57, Phe61 and Lys63 residues (Figure 1) by alanine significantly reduced the Kv1.3 blocking 
activity of mutants by about 94-, 49-, 58- and 74-fold, respectively. Since no molecular conformational 
changes were observed by circular dichroism analysis between mutants and native peptide, these data 
indicate that Hg1 mainly uses its C-terminal residues, and not those from its N-terminal, to inhibit the 
Kv1.3 channel. This is different from the known mechanism of the KTTs such as HWTX-XI and  
δ-dendrotoxin, which use their N-terminal residues to block Kv1.1 channels [14,174]. A structural 
model of the Hg1-Kv1.3 complex was computationally obtained, supporting the importance of these 
four C-terminal residues of Hg1 as the channel-interacting surface. Lys56 is the pore-blocking residue; 
Phe61 contacts residues of the channel A and D chains; and Arg57 and Lys63 mainly contacts residues 
of the channel D chain [68].  
The spider venom toxin HWTX-XI inhibited potassium channels expressed in rat dorsal  
root ganglion neurons, reducing the amplitude of potassium currents by 41.7% ± 1.8% at 1 µM 
concentration [14]. Inhibition was voltage- and concentration-dependent, with an IC50 value of  
11.6 nM. Experiments with K
+
 channel subtypes expressed in X. laevis oocytes showed that  
HWTX-XI was more active on Kv1.1 channels (78% ± 7% inhibition) than on Kv1.2 and Kv1.3  
(10% ± 2% and 28% ± 3% inhibition, respectively), although a high dose (5 µM) was needed  
(Table 2) [14].  
Studies with 18 mutants of HWTX-XI [14], which were constructed through site-directed 
mutagenesis using HWTX-XI gene as template, showed that the residue Leu6 seems to be essential for 
the K
+
 channel blocking activity (Figure 1). Its mutation to Ala or Tyr produced about 200-fold 
reduction in the inhibitory potency. The residues Arg5 and Arg25 seem to have a secondary role in the 
blocking function, once the mutations R5I and R25A produced about 14 and 4-fold reduction in the 
potassium channel activity, respectively.  
Comparisons between the primary (Figure 1) and tertiary structures of HWTX-XI and DTX-K 
provided some clues to explain why HWTX-XI is weaker than DTX K for the Kv channel blocking 
activity [14]. It was shown that the key residue for channel binding Lys3 in DTX-K is replaced by 
Asp2 in HWTX-XI, which is negatively charged and has a shorter side chain. Although this amino 
acid residue may contribute to the smaller blocking activity of HWTX-XI, the mutation D2K in this 
molecule increased the activity by only about 4-fold. It is possible that the side chain of Lys at the 
mutant was not at the molecular surface. Another difference between the two compounds is that 
HWTX-XI does not possess the equivalent residues to Trp25 and Lys26 of DTX-K, which may offer a 
hydrophobic surface for binding to the turret of Kv1.1 subunits [14].  
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6. Molecular Diversity  
As shown in this review, there are several protease inhibitors from venomous animals isolated and 
characterized from their venoms, body extracts or skin secretion so far. In addition, many of them were 
identified from transcriptomic approaches and their activity as protease inhibitors is still uncertain.  
In sea anemones, most of these polypeptides present the Kunitz-type serine protease inhibitor motif, 
with three conserved disulfide bridges (with exception of Inhibitor 4, from Rhodactis rhodostoma, 
which has only two disulfide bridges [31]), and thus are structurally homologous to the bovine 
pancreatic trypsin inhibitor (BPTI). Only two sea anemone polypeptides were shown to present distinct 
structural motifs to date—the cysteine inhibitor equistatin, with three thyroglobulin type-1 domains [43], 
and the non-classical Kazal-type elastase inhibitor (AEI) [30]. 
The tridimensional structure of BPTI determined by both crystallography and NMR reveals  
an α/β/α structural motif [19–21]. BPTI contains a hydrophobic core and three disulfide bridges  
(CI–CVI, CII–CIV, CIII–CV), and its structure is characterized by a 310-helix at its N-terminal (residues 3 
to 7), a β-hairpin of residues 18 to 35, an antiparallel β-strand involving residue 45 in contact to 
residue 21, and an α-helix formed by residues 47–56 at the C-terminal [19]. Structural-function 
relationship analysis of BPTI-enzyme complex has shown that a solvent exposed loop formed by 
residues 8 to 19 is highly complementary to the enzyme active site (S1 pocket), wherein the P1 residue 
(Lys15 in BPTI) deeply penetrates to interact with the S1 binding pocket of the protease. Trypsin, 
which has Asp189 as its S1 site, is particularly suited to interact with the basic side chains of Lys15 
from BPTI [175,176] (Figure 2E). 
Regarding the serine superfamily of PIs, three major classes are designated as trypsin-like 
(positively charged residues Lys/Arg preferred at P1), elastase-like (small hydrophobic residues Ala/Val 
at P1) or chymotrypsin-like (large hydrophobic residues Phe/Trp/Tyr/Leu/Val at P1) [12,84,177]. The 
P1 site residues Met, Asn and His for chymotrypsin binding were also reported [50,59,118,177,178]. A 
catalytic triad of residues (usually Ser, His and Asp) on the enzymes’ pocket is responsible for amide 
bond hydrolysis. Analysis of various mutants of BPTI and other trypsin inhibitors revealed that the 
interaction inhibitor:trypsin is almost independent of the nature of the basic residue at P1 position, with 
no significant changes in the association energies with trypsin after the mutation K15R in BPTI [179]. 
By contrary, inhibition for kallikrein favors Arg over Lys [180,181], while plasmin inhibition is 
enhanced by Lys at P1 site [182]. The P1′ site of venom trypsin/chymotrypsin inhibitors is occupied by 
a hydrophobic amino acid residue (Ala, Gly and Phe), being the Ala residue the most commonly used 
(Figure 1). 
The solution structure of ShPI-1, a Kunitz-type protease inhibitor purified from the sea anemone 
Stoichactis helianthus, was determined by NMR spectroscopy [36]. Despite low sequence similarity 
between the two polypeptides (~35%), ShPI-1 (Figure 2A) has an almost identical molecular 
architecture to BPTI, with a 310-helix involving residues 1 to 5, a twisted β-harpin of residues 16 to 33, 
a single-residue antiparallel β strand of residue 43 and an α-helix at the C-terminal (residues 45 to 54) [36]. 
Moreover, the crystallographic structure of ShPI-1 in complex with bovine pancreatic trypsin was 
revealed (PDB ID: 3M7Q) [39]. The overall structure of this complex is highly similar to the homologous 
complexes with BTPI (PDB ID: 2FTL and 3OTJ) [183], which is characterized by the lowest 
dissociation constant known so far for an inhibitor-protease interaction (Ki of 6 × 10
–14
 M) [184]. 
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Around 40% of the total interactions at the interface rShPI-1A:trypsin are formed by Lys13 at P1 
position (Figures 1 and 2A), whose side chain interacts with Asp189 at the trypsin catalytic pocket, 
similarly to BPTI [175]. Additional contributions to the stability of the complex ShPI-1:trypsin are 
indicated by residues Arg11 (P3 site) and Ile32. The side chain of Arg11 points directly into a pocket 
on the enzyme surface (S3 site), establishing additional H-bonds at the complex in comparison to 
BPTI, whose proline residue at this position does not deeply enter the S3 pocket due to its cyclic 
nature [178,183]. The in silico Arg11Ala mutation in ShPI-1 led to a 10-fold increase in the theoretical 
Ki value against trypsin.  
Figure 2. Tridimensional structures of polypeptides from venomous animals with the 
Kunitz-type inhibitor motif (A–D) and bovine pancreatic trypsin inhibitor (BPTI): trypsin 
complex (E). (A) ShPI-1 (PDB code 1SHP) from the sea anemone Stoichactis helianthus; 
(B) conkunitzin-S1 (PDB code 2CA7) from the cone snail Conus striatus; (C) HWTX-XI 
(PDB code 2JOT) from the spider Ornithoctonus huwena; (D) anntoxin (PDB code 2KCR) 
from the frog Hyla annectans; (E) BPTI:trypsin complex (PDB code 3OTJ). The structures 
are shown as ribbon diagrams, where α-helixes are indicated by red color, β-strands by 
yellow, 310-helix by dark blue; and disordered structure by silver. In detail, Lys residue at 
P1 position (cyan at A, C and D). In BPTI:trypsin complex, interacting amino acid residues 
are shown in dark grey for BPTI (Lys15 residue at P1 position) and in orange for trypsin 
(Asp189 at S1 position). A, C, D and E were obtained with the software VMD (visual 
molecular dynamics) [185], whereas B was obtained with the software Discovery Studio 3.5 
(Accelrys, Inc., San Diego, CA, USA). 
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The sea anemone protease inhibitors kalicludines (AsKC1 to AsKC3) and ShPI-2, from  
Anemonia sulcata and Stoichactis helianthus, respectively, along with some Kunitz-type PIs from 
snakes, scorpions and spiders (Figure 1) also present Arg residue at the P3 position. Sea anemone 
kalicludines contain the residues Arg15 and Ala16 at P1 and P1′ positions, respectively, which are 
important for good trypsin binding. However, the presence of Pro19—equivalent to Pro21 in 
dendrotoxin, which is suggested to cause unfavorable feature for trypsin binding [153]—may explain 
the weaker inhibitory activities of kalicludines in comparison to BPTI, which has an Ile residue at the 
equivalent position [27].  
The molecular diversity of Kunitz-type inhibitor homologs in Heteractis crispa was examined by 
using PCR-based cloning techniques, revealing that the H. crispa polypeptides are encoded by a 
multigene superfamily, which was divided into four distinct groups according to the N-terminal amino 
acid residues (GS-, RG-, GG-, and GN-) [15]. According to the nature of P1 residue, 33 deduced 
mature GS-polypeptides were categorized into three groups: group I (with Lys at P1 site), group II 
(Thr at P1), and group III (Arg at P1). Most of transcripts were placed in group I (66.1%),  
24% generated group II, and 9.9% was in group III. Phylogenetic analysis suggested that the  
GS-polypeptide genes, as well as those from other sea anemone Kunitz-type inhibitors, have evolved 
from a common ancestor. The ancestral polypeptide more likely contains Arg as the P1 residue and 
Gly in position 38, as these important residues are shared by most of sea anemone Kunitz-type 
inhibitors (Figure 1) and members of group III [15]. 
The P1 site is occupied by a Thr residue, instead of Lys/Arg, in the sea anemone polypeptides 
InhVJ, Jn-IV and APHC1-APHC3 (Figure 1). Because the serine protease inhibitor InhVJ, from the 
sea anemone Heteractis crispa, is homologous to ShPI-1 (87% identity), its spatial structure could be 
model using the structure of ShPI-1 as a template, and the model was used to predict the structure of 
the complex InhVJ:trypsin [47]. Docking analysis showed a smaller number (three) of H-bond formed 
by the P1 Thr residue of InhVJ with the trypsin active site in comparison to those of ShPI-1 (five) and 
of BPTI (seven), which correlate well with the decreasing Ki values of their complexes. Electrostatic 
interactions and H-bonds of Glu45 at the weak contact site with protease Lys60 and Tyr39 were also 
important to stabilize the InhVJ:trypsin complex [47]. The conformational stability of InhVJ was 
analyzed by circular dichroism (CD) spectroscopy [186]. It was shown to be highly stable to changes 
in temperature and pH. Even after 70 °C, which is the point of the thermal conformational transition of 
the polypeptide, InhVJ still retained 80% of the inhibitory activity. Significant changes were observed 
on the level of tertiary structure of the molecule in the pH range 11.0–13.0, which may be explained by 
the ionization of tyrosine residues. InhVJ is conformationally stable at a low pH value (2.0). 
Quenching experiments showed that two tyrosine residues are completely accessible for the quencher, 
whereas the third residue is partially accessible [186]. 
From cone snail, only few PIs have been studied. Although sharing similar size and tridimensional 
structure to the Kunitz-type inhibitors, conkunitzin-S1 (Figure 2B) has only two disulfide  
bridges [105]. The solution structure of conkunitzin-S1 consists of a 310-helix of residues 6–8,  
a contorted β-hairpin of residues 20–36, and an α-helix in the C-terminus (residues 50–56). The CI–CIV 
pair connects the two helices, and the C-terminal helix is connected to the β-sheet by the disulfide 
bridge between CII and CIII [187]. To evaluate the importance of the third disulfide bond to the  
K
+
-channel blocker activity, a double cysteine mutant (Conk-S1
CC
) with the additional cysteine bridge 
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between the positions 16 and 40 was constructed. Interestingly, wild type and mutant Conk-S1 
displayed the same inhibitory activity on Shaker channels [105]. Most of the K
+
-channel blockers from 
venomous animals have conserved residues, which are responsible for block of the ion conduction 
pore and promote a high affinity binding within the K
+
 channel pore vestibule, such as a lysine residue 
and an aromatic residue at 6.6 ± 1.0 Å from the α carbon of that lysine, respectively, a motif termed 
the “functional dyad” [188]. However, different interaction mechanisms have been described, among 
them, the “basic ring” (four or five non-identical basic residues that might stabilize the interaction with 
the channels) [189]. In the crystal structure of conkunitzin-S1, positive electrostatic potential is 
concentrated on one side of the molecule and there is apparently no dyad-like lysine-hydrophobic pair, 
suggesting that conkunitzin-S1 could interact with K
+
-channels through its arrangement of positively 
charged residues. 
The scorpion mature peptide rLmKTT-1b (SdPI), from Lychas mucronatus, presents sequence 
similarity with Kunitz-type inhibitors. However, different from the typical Kunitz-type motif, 
rLmKTT-1b—along with the scorpion toxins rLmKTT-1a, rLmKTT-1c, and rBmKTT-1 [68]—possess 
a unique cysteine framework, where the normal CII–CIV disulfide bridge is absent, such as 
conkunitizin-S1, but two additional cysteine residues at the C-terminus of the mature peptide might 
generate a new disulfide bridge. As a result, a distinct disulfide assignment may be generated  
(Figure 1) [16]. Also from scorpion venom PIs, recombinant BmKTT-2 was found to form four 
disulfide bridges (Table 1 and Figure 1), which is different from all known Kunitz-type animal  
toxins [68]. AvCI, from the spider Araneus ventricosus (Table 1) also presents the Kunitz-type motif 
and four disulfide bridges, and although a protease inhibitory activity was observed, this toxin was 
suggested to derive from the spider whole body, but not from venom [71]. 
These propositions were recently revealed with the solution structure of rLmKTT-1a [99]. NMR 
experiments of rLmKTT-1a showed a typical Kunitz-type fold, characterized by a N-terminal helix 
from Lys2 to Cys4, a double-stranded anti-parallel β-sheets from Phe17 to Asn23 and Lys28 to Tyr34, 
and a C-terminal helix from Asp49 to Ala55, where the disulfide link between Cys51 and Cys59 is 
presented. Although the sequence similarity is low between LmKTT-1a and classical Kunitz-type 
toxins, its structure resembles the fold of other inhibitors, such as conkunitzin-S1, dendrotoxin, 
HWTX-XI, and APEKTx1, suggesting that, despite of molecular diversity, these Kunitz-type peptides 
hold a structural conservation [99]. The mutant LmKTT-1a-C51A/C59A, with the same disulfide 
bridge pattern as those of cone snail conkunitzin-S1, and preserving a secondary structure similar to 
LmKTT-1a, presented a 5-fold lower trypsin inhibitory activity than the native LmKTT-1a, but the 
same Kv1.3 channel blocking activity.  
The LmKTT-1a gene structure contains two introns in the mature peptide and differs from the 
genomic organization of the four families of scorpion KTxs, α-, β-, γ-, and κ-KTxs. Considering the 
structural, and functional features, and the genomic organization of scorpion Kunitz-type toxins, it has 
been proposed a new KTx subfamily to classify these scorpion peptides, the δ-KTx, where the seven 
members would be divided in three groups based on the disulfide bridge patterns [99]. 
Molecular dynamics simulation with a proposed rLmKTT-1b:trypsin complex model [16], based on 
the BPTI interaction with trypsin, showed the active site formed by Lys12, Gly13, Lys14 and Ala15 
(Figure 1) inside the S1 pocket of trypsin. In the proximity of the active site there were also strong 
polar and nonpolar interactions among residues. Peptide Phe17 may also contribute to enhancing the 
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rLmKTT-1b:trypsin interaction. The side chain of Lys14, the P1 residue of rLmKTT-1b, protrudes 
inside the S1 pocket and forms hydrogen bonds with trypsin residues Asp176 and Ser192. Therefore, it 
is suggested that besides its new disulfide bridge connection, rLmKTT-1b likely interacts with trypsin 
in a similar way to other Kunitz-type toxins [16].  
Recently, four putative serine PIs belonging to the Ascaris-type peptides were identified in scorpion 
cDNA libraries [69]. Members of the Ascaris-type peptides’ family are characterized by four short  
β-strands arranged in two approximately perpendicular β-sheets and stabilized by five disulfide  
bridges [144].  
The NMR solution structure of spider Kunitz-type toxin HWTX-XI (Figure 2C) [14] resembles the 
structures of BPTI and DTX-K [19,190]. In the N-terminal of HWTX-XI, from Thr3 to Arg5, there is a 
310-helix, and in the C-terminal, there is an α-helix from Gln45 to Cys52 and a triple-stranded  
anti-parallel β-sheet formed by Glu18–Asn23, Thr26–Ile31 and Lys41–Phe42. The two helixes are 
connected by the disulfide bond Cys4–Cys52, and the α-helix is connected to the β-sheet by the 
disulfide bond Cys27–Cys48.  
The studies with 18 mutants of HWTX-XI [14] showed that Lys14 is the main amino acid residue 
responsible for the trypsin inhibition function, since the mutation K14N reduced in approximately  
10
5
-fold the inhibitory potency and K14A presented no trypsin binding activity at all. Thus, HWTX-XI 
counts with the presence of two separate and functionally independent sites—one for serine protease 
inhibition and another for potassium channel blockage (Figure 1), as discussed in the previous section. 
By comparing the primary and tertiary structures of HWTX-XI and BPTI, the authors suggest some 
possible reasons for making HWTX-XI a stronger trypsin inhibitor than BPTI [14]. First, the 
replacement of Arg21 in BPTI by the smaller and non-charged residue Ser16 in HWTX-XI (Figure 1) 
increases the interaction of Lys14 with the negatively charged residue Asp189 at the bottom of the S1 
pocket of trypsin. Second, the Phe17 of HWTX-XI has a larger side chain (phenyl group) than Ile22 of 
BPTI, and this may lead to a broader hydrophobic surface to interact with the hydrophobic pocket 
formed by Phe41 and Lys60 of trypsin. Third, the amino groups of the long hydrophobic side chain of 
Arg12 of HWTX-XI fit perfectly the positive pocket formed by the hydroxyls of Lys145, Ser146 and 
Gly148 of trypsin. These interactions may be strengthened by the potential hydrogen bonds between 
them [14]. 
As shown, most of snake venom serine protease inhibitors characterized to date also belong to the 
Kunitz-type motif, although some of them do not present inhibitory activity due to the absence of the 
key residues at P3–P3′ (Figure 1).  
Among the known protease inhibitors from venomous animals, PIs from Anurans display the major 
variety in structure length and number of cysteine residues. At least six different classes can be 
distinguished: long PIs, consisting of a basic single chain glycoprotein varying from 22 to 60 kDa; 
inhibitors with 56–61 amino acid residues and five disulfide bridges that, similar to scorpion SjAPI, 
are also members of the Ascaris-type peptides’ family; Kazal-type serine protease inhibitors varying 
from 52 to 78 amino acid residues and containing three disulfide bridges; Kunitz-type inhibitors also 
with three disulfide bridges and 57–62 residues long; long-chain inhibitors with 60 residues and only 
two disulfide bridges; and the two smallest protease inhibitors from venomous animals, with  
17–18 amino acid residues and a single disulfide bridge.  
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The mature OGTI, from the frog Odorrana grahami, is one of the smallest protease inhibitors ever 
found (17 amino acid residues) and contains a six-residue loop cross-linked by one disulfide  
bridge [86]. Circular dichroism spectroscopy analysis indicated that its conformational distribution is 
essentially random (94.8%). The importance of Lys13 to the inhibitory activity was confirmed by the 
mutation K13A, being the mutated peptide not active against trypsin [86].  
The Bowman-Birk type trypsin inhibitor HV-BBI, from the frog Huia versabilis, is also one of the 
smallest PIs characterized from animals to date [87]. This 18-amino acid residue trypsin inhibitor 
contains a disulfide loop between Cys5 and Cys15. Substitution of Lys8 at the presumed P1 position in 
the conserved canonical BBI motif, -TKSIPP-, by Arg resulted in 3-fold decrease in trypsin inhibitory 
activity (Ki of ~57 nM), whereas replacement by the aromatic residue Phe resulted in complete 
ineffectiveness. Both the Lys-P1 and Arg-P1 variants had no inhibitory activity against chymotrypsin 
even at a concentration of 100 µM. In contrast, the Phe-P1 variant presented a modest chymotrypsin 
inhibitory activity (Ki of ~389 nM). Thus, the Lys residue that occupies the P1 position seems to be 
optimal for potency of action against trypsin [87]. 
The amphibian peptide anntoxin, from Hyla annectans, is similar to conkunitzin-S1, having the 
same four cysteine framework and spacing [85]. The NMR structure of the recombinant peptide 
(Figure 2D), which presented protease inhibitory activity equal to the native peptide, was also similar 
to those of conkunitzin-S1 [105]. Its structure consists of a twisted β-hairpin (Thr20–Phe34),  
an α-helix (Leu49–Ala59), and a short 310-helix (Tyr4–Cys6) in the N-terminus. Their two disulfide 
bridges are formed by Cys6–Cys56 and Cys31–Cys52. In anntoxin, the conserved trypsin inhibitor 




 [85].  
Two other Kunitz-type inhibitors characterized from Anurans, KTPI (Kunitz-type protease inhibitor) 
and KSCI, were isolated from Dyscophus guineti and Kassina senegalensis, respectively [17,84], and 
their P1 residues (Figure 1) are in complete agreement with their trypsin (Arg16 in KTPI) and 
chymotrypsin (Phe17 in KSCI) inhibitory activities.  
Among the few protease inhibitors functionally characterized from wasp and bees until now, three 
of them (bicolin, Bi-KTI and Bt-KTI) share the three conserved disulfide bridges of Kunitz/BPTI-type 
inhibitors (Figure 1). Besides having an unusual P1 residue (Gln15), bicolin, from the venom of the 
wasp Vespa bicolor, still shows trypsin and thrombin inhibitory activity [88]. 
7. Therapeutic Potential 
Besides being one of the most studied small globular proteins used as tool for protein 3D structure, 
protein/protein interaction, and molecular recognition studies, the clinical use of BPTI has been 
advised in cardiac surgery and orthotopic liver transplantation. BPTI has a very high specificity for 
plasmin, and exerts a significant reduction in hemorrhagic complications, blood-transfusion requirements, 
and the inflammatory status associated to extra-corporeal circulation [191,192]. Indeed, patients treated 
with BPTI submitted to repeated cardiac surgery, valve replacement and coronary-artery bypass grafting, 
presented up to 80 percent less blood loss and up to 60 percent lower transfusion requirements than 
control groups [193,194]. The potential use of textilin-1, a serine protease inhibitor isolated from snake 
venom, is proposed to reduce blood loss during cardiopulmonary surgery [7,122,195]. 
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As broadly known and emphasized in the present review, proteases are essential for most 
physiological processes and, because of that, protease inhibitors have a wide therapeutic potential on 
cancer and on CNS, cardiovascular, inflammatory and neurodegenerative diseases, including 
Alzheimer's disease (reviewed in [11]), as well as on viral and parasitic infections associated to 
overexpressed or unregulated enzyme activity. More than 50 human diseases have been associated to 
specific mutations in protease genes [196]. 
Cysteine protease inhibitors have been proposed as antimalarial drugs, because of the critical role 
for these proteases in hemoglobin hydrolysis at the trophozoite stage of malaria parasite [197]. These 
proteases also take part in many human physiological pathways such as antigen processing and 
prohormone activation, as in some diseases including arthritis, Alzheimer’s disease, and cancer-cell 
invasion, reinforcing the importance of finding new cysteine protease inhibitors. 
According to practice guidelines published by the American Association for the Study of Liver 
Diseases (AASLD) in 2011, the best treatment for genotype 1 chronic hepatitis C virus (HCV) 
infection is a triple therapy that consists of ribavirin and pegylated interferon-α together with a serine 
protease inhibitor (telaprevir or boceprevir) [198]. In the Acquired Immunodeficiency Syndrome 
(AIDS), the HIV protease has become an important therapeutic target leading to the development of 
several protease inhibitors [199,200], and their use as therapeutic drugs has been associated with a 
drastic reduction in AIDS morbidity and mortality, although the benefits have been compromised by 
viral mutation and drug-resistance [201]. 
8. Conclusions 
Several protease inhibitors have been isolated from venomous animals, mainly sea anemones, 
snakes and Anurans. Nevertheless, the characterization of PIs from scorpions, spiders and 
Hymenopterans has attracted increasing interest from the scientific community, whereas those from 
cone snails remain less studied. Among the serine protease inhibitors, these polypeptides usually have 
distinct specificity for different proteases, such as trypsin, chymotrypsin, elastase, plasmin, and others. 
Because most of toxins from venomous animals are characterized as Kunitz-type serine protease 
inhibitors and present similar tridimensional structural motifs, their specificity towards serine proteases 
is mainly associated with P1 amino acid. However, besides the amino acid residues surrounding the 
reactive site, the residues present in the weak contact loop are also important for the different 
interactions with various serine proteases. 
In addition to the protease inhibitory activity, some of these polypeptides are also blockers of 
potassium channels, being the site of interaction with these channels different from and independent of 
that for the protease binding. Evolutionary features suggest that new potassium channel blockers or 
dual-function neurotoxins have been originated from ancient molecules.  
Because of the increasing diversity of known Kunitz-type polypeptides, primary sequence 
comparisons, along with studies comprising site-directed mutagenesis and conformational analysis, 
could help better understand which amino acid residues are essential for protease inhibition and also 
for the dual-function. By analyzing the sequences of BmKTT-1, BmKTT-2 and BmKTT-3 (Figure 1), 
for example, it is possible to propose that the higher potency of BmKTT-1 on Kv1.3 channels in 
relation to these other toxins is because only BmKTT-1 possesses the dyad residues Lys2 and Leu5 
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equivalent to those in dendrotoxins. Conversely, LmKTT-1a also possesses these dyad residues, but 
displays little blocking activity. One possible explanation could be the lack of the second cluster of key 
residues in the equivalent β-turn region of dendrotoxins. The sea anemone toxin APEKTx1, in turn, is 
a potent blocker of Kv1.1 channels, and although not containing the corresponding Lys5 and Leu9 
residues of α-DTX and DTX-I, it contains the residues Leu7 and Lys10, and also the second cluster of 
key residues. These two regions could be responsible for the higher potassium channel activity in 
relation to SHTX-3, which is a weak channel blocker. However, the sea anemone kalicludines, which 
present most of the key residues for K
+
 channel blocking activity, are weak inhibitors of Kv1.2 
channels. Thus, it would be interesting to test them on different subtypes of potassium channels, such 
as Kv1.1 and Kv1.3. 
This sort of analysis could lead to the design of more potent protease inhibitors and dual-function 
polypeptides, and also to their strategically minimization in size, fashioning enhanced and low-priced 
drugs for diverse therapeutic and biotechnological applications. Moreover, comparative analysis could 
lead to a global evolutionary model that comprises all these PIs, which are undoubtedly provided with 
important physiological functions in the source organisms. 
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